REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study

Summary

The primary objective is to compare \& evaluate between the treatment groups the changes in decline/reduction of HIV viral load changes in the Remune + Amplivax group vs the Amplivax placebo groups. Additional objectives include changes in WBC White Blood Cell counts \& CD4+ \& CD8+ T cell counts along with increased HIV immunity.

Timeline

Start

2017-06

Primary completion

2019-06

Completion

2019-06

Drugs

Indications